NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Large Decrease in Short Interest

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 135,900 shares, a decline of 29.3% from the August 15th total of 192,200 shares. Based on an average daily volume of 286,900 shares, the short-interest ratio is presently 0.5 days.

NovaBay Pharmaceuticals Price Performance

NYSEAMERICAN:NBY traded up $0.01 on Monday, hitting $0.49. The stock had a trading volume of 40,702 shares, compared to its average volume of 235,233. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $17.74. The firm has a market capitalization of $2.06 million, a price-to-earnings ratio of -0.05 and a beta of 2.82.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) EPS for the quarter. The business had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative return on equity of 146.20%. As a group, equities analysts anticipate that NovaBay Pharmaceuticals will post -2.54 earnings per share for the current fiscal year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.